This pandemic required communication among specialists and primary care. In this COVID-19 panel, faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community, Irvine, CA

Daniel A. Solomon, MD

Associate Physician, Division of Infectious Diseases, Brigham and Women's Hospital, Instructor of Medicine,, Harvard Medical School, Boston, MA

Although hepatocellular carcinoma (HCC) screening can improve survival for patients, it is underused in clinical practice. Join two faculty experts as they discuss the urgency for early identification of HCC in primary care, and learn about the changing epidemiology of HCC and how primary care providers can support patients during their journey. This program also features patient/caregiver videos and interactive Q&A sessions.

Amit Singal, MD, MS

Professor of Medicine, Willis C. Maddrey Chair in Liver Disease, Chair of Hepatology, Medical Directory of Liver Tumor Program, UT Southwestern Medical Center, Dallas, TX

Ghassan Abou-Alfa, MD, MBA

Attending Physician, Memorial Sloan-Kettering Cancer Center, Professor of Medicine, Weill Medical College, Cornell University, New York, NY

Supported by an educational grant from Genentech, a member of the Roche Group

This activity will provide an evidence-based approach to the diagnosis and management of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.

Philip Schoenfeld, MD, MSEd, MSc

Chief (Emeritus) - Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI

Supported by Supported by an educational grant from AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc..

The entire field of migraine is witnessing a profound and unprecedented transformation with new therapeutic options now available to address serious unmet medical needs and patient burden. The new options range from monoclonal antibodies (mAbs) targeting the CGRP ligand or receptor for migraine prevention, to a selective serotonin agonist, to oral CGRP-targeting agents (gepants) now approved for both preventive and acute treatment. These new advances are creating a vitality and excitement in the field not seen since the advent of triptans more than 2 decades ago.

Stewart J. Tepper, MD, FAHS

Professor of Neurology, Geisel School of Medicine at Dartmouth, Director, Dartmouth Headache Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Merle Diamond, MD

Clinical Assistant Professor, Department of Medicine, Rosalind Franklin Universty of Medicine and Science/Chicago Medical School, President and Managing Director, Diamond Headache Clinic, Chicago, IL

Supported by Biohaven Pharmaceuticals

Are you frequently challenged by the task of early and accurate diagnosis of Alzheimer’s disease (AD) as a PCP? Are you keen to the possibility of collaboration with secondary care specialists to optimize early recognition and management of AD? Are you up to date on the latest developments and clinical pearls of Alzheimer’s research in order to tailor patient-specific approaches for AD? This live virtual meeting will examine these challenges and provide effective strategies to meet them head on.

This session will provide you with the latest information regarding the role of PCPs and their extended care team in early diagnosis of AD, effective methods to address racial and ethnic barriers to dementia-related care, and important clinical pearls to encourage collaboration among PCPs and secondary care specialists. In addition, learn the intricacies surrounding patient-specific management considerations, as well as the role of recently approved and emerging disease-modifying therapies for the management of AD.

Richard S. Isaacson, MD

Director, Center for Brain Health, Director, Alzheimer’s Prevention Clinic, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, Adjunct Associate Professor of Neurology, Department of Neurology, Weill Cornell Medicine/NewYork-Presbyterian, New York City, NY

Katherine E. Galluzzi, DO, CMD, FACOFP

Professor and Chair, Department of Geriatrics, Director, Comprehensive Care , Philadelphia College of Osteopathic Medicine, Philadelphia, PA

Supported by Eisai

What do primary care providers need to know about diabetes, atrial fibrillation, and geriatric cancer screening? Join expert faculty as they review important questions they get asked about these topics! 

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine, Harvard Medical School, Director, Division of CME, Beth Israel Deaconess Medical Center, Boston, MA

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS) , Providence Heart Institute, Providence St. Joseph Health , Portland, OR

Lee A. Lindquist, MD, MPH, MBA

Chief of Geriatrics, Northwestern University Feinberg School of Medicine, Chicago, IL